Business · 1 sources covering this

Piramal Pharma Q2 Results: Swings To Profit, Upgrades FY27 Revenue Growth Outlook

Piramal Pharma's CDMO business was the key growth driver during the quarter, reporting 28% revenue growth on the back of strong order inflows and execution.

Share:WhatsApp X Reddit Facebook LinkedIn

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

NDTVCenter·2h ago
Piramal Pharma Q2 Results: Swings To Profit, Upgrades FY27 Revenue Growth Outlook
Piramal Pharma's CDMO business was the key growth driver during the quarter, reporting 28% revenue growth on the back of strong order inflows and execution.
Read at NDTV →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://hindustansphere.com/embed/cluster/16cbca0ecc59832409543cc101d382ceedee4411"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Piramal Pharma Q2 Results: Swings To Profit, Upgrades FY27 Revenue Growth Outlook"></iframe>

Piramal Pharma Q2 Results: Swings To Profit, Upgrades FY27 Revenue Growth Outlook

How 1 sources are covering this

Piramal Pharma Q2 Results: Swings To Profit, Upgrades FY27 Revenue Growth Outlook

More from Business

Samvat 2083: What Would Make Brokers Bullish Again On Indian Markets? Axis Lists Its Triggers

UP to begin work on key industrial projects ahead of Assembly elections

BFSI Insight Summit: Health insurance leaders split on dedicated regulator

AI poses new risks, makes assessment more complex: General insurers

Reader

Trust & legal

Across the network